|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kerkar SP and Restifo NP: Cellular
constituents of immune escape within the tumor microenvironment.
Cancer Res. 72:3125–3130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ostrand-Rosenberg S: Tolerance and immune
suppression in the tumor microenvironment. Cell Immunol. 299:23–29.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ruffell B and Coussens LM: Macrophages and
therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prenen H and Mazzone M: Tumor-associated
macrophages: A short compendium. Cell Mol Life Sci. 76:1447–1458.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goswami KK, Ghosh T, Ghosh S, Sarkar M,
Bose A and Baral R: Tumor promoting role of anti-tumor macrophages
in tumor microenvironment. Cell Immunol. 316:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aras S and Zaidi MR: TAMeless traitors:
Macrophages in cancer progression and metastasis. Br J Cancer.
117:1583–1591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qian BZ and Pollard JW: Macrophage
diversity enhances tumor progression and metastasis. Cell.
141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mittal D, Gubin MM, Schreiber RD and Smyth
MJ: New insights into cancer immunoediting and its three component
phases-elimination, equilibrium and escape. Curr Opin Immunol.
27:16–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mantovani A and Allavena P: The
interaction of anticancer therapies with tumor-associated
macrophages. J Exp Med. 212:435–445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang F, Yang L, Gao Q, Huang L, Wang L,
Wang J, Wang S, Zhang B and Zhang Y:
CD163+CD14+ macrophages, a potential immune
biomarker for malignant pleural effusion. Cancer Immunol
Immunother. 64:965–976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang L, Wang F, Wang L, Huang L, Wang J,
Zhang B and Zhang Y: CD163+ tumor-associated macrophage
is a prognostic biomarker and is associated with therapeutic effect
on malignant pleural effusion of lung cancer patients. Oncotarget.
6:10592–10603. 2015.PubMed/NCBI
|
|
15
|
Ohtaki Y, Ishii G, Nagai K, Ashimine S,
Kuwata T, Hishida T, Nishimura M, Yoshida J, Takeyoshi I and Ochiai
A: Stromal macrophage expressing CD204 is associated with tumor
aggressiveness in lung adenocarcinoma. J Thorac Oncol. 5:1507–1515.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Loyher PL, Hamon P, Laviron M,
Meghraoui-Kheddar A, Goncalves E, Deng Z, Torstensson S, Bercovici
N, Baudesson de Chanville C, et al: Macrophages of distinct origins
contribute to tumor development in the lung. J Exp Med.
215:2536–2553. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jackute J, Zemaitis M, Pranys D,
Sitkauskiene B, Miliauskas S, Vaitkiene S and Sakalauskas R:
Distribution of M1 and M2 macrophages in tumor islets and stroma in
relation to prognosis of non-small cell lung cancer. BMC Immunol.
19:32018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao
YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, et al:
Tumor-associated macrophage-induced invasion and angiogenesis of
human basal cell carcinoma cells by cyclooxygenase-2 induction. J
Invest Dermatol. 129:1016–1025. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chung FT, Lee KY, Wang CW, Heh CC, Chan
YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, et al:
Tumor-associated macrophages correlate with response to epidermal
growth factor receptor-tyrosine kinase inhibitors in advanced
non-small cell lung cancer. Int J Cancer. 131:E227–E235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou
W, Wang J, Yang B, Zhao Y, Rao Z and Gao J: M2-polarized
macrophages contribute to the decreased sensitivity of EGFR-TKIs
treatment in patients with advanced lung adenocarcinoma. Med Oncol.
31:1272014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng H, Chen B, Huang W, Tang Y, Jiang Y,
Zhang W and Huang Y: Reprogramming tumor-associated macrophages to
reverse EGFRT790M resistance by dual-targeting
codelivery of gefitinib/vorinostat. Nano Lett. 17:7684–7690. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gadgeel SM and Wozniak A: Preclinical
rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for
epidermal growth factor receptor inhibitor-resistant non-small-cell
lung cancer. Clin Lung Cancer. 14:322–332. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pérez-Ramírez C, Cañadas-Garre M, Molina
MÁ, Faus-Dáder MJ and Calleja-Hernández MÁ: PTEN and PI3K/AKT in
non-small-cell lung cancer. Pharmacogenomics. 16:1843–1862. 2015.
View Article : Google Scholar : PubMed/NCBI
|
